Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of IL-1R2 cell factor in preparing medicament for treating hepatic failure

A technology for liver failure and cytokines, applied in the fields of molecular medicine, biomedicine, and clinical medicine, which can solve problems such as low efficiency

Inactive Publication Date: 2019-08-30
ZHEJIANG UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

IL-1R2 binds IL-1β but binds IL-1α and IL-1Ra less efficiently

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of IL-1R2 cell factor in preparing medicament for treating hepatic failure
  • Application of IL-1R2 cell factor in preparing medicament for treating hepatic failure
  • Application of IL-1R2 cell factor in preparing medicament for treating hepatic failure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Embodiment 1: Injection containing IL-1R2 cytokines treats a large animal (young pig) model of liver failure

[0043] Animal model: 30 male Chinese young pigs (8-10 kg) were randomly divided into two groups, 15 in each group. Each young pig was injected with D-gal 1.5g / kg in the jugular vein to create a liver failure model.

[0044] Test group: Multiple intravenous injections of IL-1R2 injection at fixed time points after D-gal injection, dose: 10ml / kg, twice a day.

[0045] Control group: inject the same amount of normal saline without IL-1R2.

[0046] Neither the control group nor the experimental group received other drug treatment.

[0047] figure 1 It is a schematic diagram of the survival time curves of the young pigs of the experimental group and the control group, showing the survival rate of the young pigs of the experimental group and the control group. The results showed that the 3-day survival rate of young pigs in the treatment group containing IL-1R2 c...

Embodiment 2

[0048] Example 2: The small animal (rat) model of liver failure treated by lyophilized powder injection containing IL-1R2 cytokine

[0049] Animal model: 100 male rats (200-250 g) were randomly divided into two groups, 50 in each group. Each rat was intraperitoneally injected with D-gal 1.5g / kg to make a liver failure model. The IL-1R2 lyophilized powder and water for injection are prepared into a suspension.

[0050] Test group: 4 ml of IL-1R2 lyophilized powder suspension was intraperitoneally injected at fixed time points after D-gal injection, twice a day.

[0051] Control group: inject the same amount of normal saline without IL-1R2.

[0052] Both the control group and the experimental group received no other drug treatment.

[0053] figure 2 Schematic diagram of the survival time curves of rats in the experimental group and the control group, figure 2The survival rates of the experimental group and the control group rats were shown: the results showed that the rat...

Embodiment 3

[0054] Example 3: The suspension containing IL-1R2 cytokines treats a rabbit model of liver failure

[0055] Animal model: 40 adult male rabbits (2000-2500 g) were randomly divided into two groups, 20 in each group. Each rabbit was intramuscularly injected with D-gal 1.5g / kg to make a liver failure model.

[0056] Test group: intramuscular injection of 20 ml of IL-1R2 suspension at fixed time points after D-gal injection, twice a day.

[0057] Control group: inject the same amount of normal saline without IL-1R2.

[0058] Both the control group and the experimental group received no other drug treatment.

[0059] image 3 It is a schematic diagram of the survival time curves of rabbits in the experimental group and the control group, image 3 The survival rate of the rabbits in the experimental group and the control group is shown: the results show that the survival rate of the rabbits in the IL-1R2 treatment group is 90% at 1 day and 80% at 7 days, while the survival rate...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of an IL-1R2 cell factor in preparing medicament for treating hepatic failure. The medicament comprises pharmaceutically acceptable excipients, antioxidants and carriers of the IL-1R2 cell factor. According to the invention, based on polycentric and prospective large-cohort population and samples, multiple technological methods of transcriptome sequencing, multi-omics correlation analysis, qRT-PCR, animal experiment in vivo validation and the like are adopted, cross validation is carried out from different angles, the IL-1R2 cell factor is found to be capable of being applied to the effective preparation of the medicine for treating the hepatic failure, and can be matched with different solvents and stabilizers to produce the medicines with different dosage forms and dosages. IL-1R2 is one of the members of ABCA superfamily, and has the main functions of mediating transmembrane transport of lipid and adjusting metabolic disorders such as hepatocyte fatty degeneration in the hepatic failure process.

Description

technical field [0001] The invention belongs to the fields of clinical medicine, molecular medicine and biomedicine, and is a new technology for the treatment of liver failure with IL-1R2 cytokine series drugs. in the application. Background technique [0002] Liver failure is a kind of disease caused by extensive necrosis of the liver caused by various reasons. Except for orthotopic liver transplantation, there is currently no specific treatment. However, due to the severe shortage of donor livers, a large number of patients died while waiting for liver transplantation. Clarifying the pathogenesis of liver failure and early treatment targeting the mechanism can effectively block the progression of the disease and reduce the mortality rate, which is of great significance to the treatment of liver failure. [0003] Interleukin receptor 1R2 (IL-1R2) is a member of the interleukin 1 receptor family (IL-1R), which includes 10 soluble proteins with similar structures. IL-1R2 ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/20A61P1/16
CPCA61K38/2013A61P1/16
Inventor 李君陈新李江梁茜李佳琪江静
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com